Masimo Corporation (MASI)
USD 170.63
(-1.98%)
USD 170.63
(-1.98%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 136.5 Million USD | -21.76% |
| 2022 | 210 Million USD | -23.86% |
| 2021 | 275.82 Million USD | 7.82% |
| 2020 | 255.82 Million USD | 15.64% |
| 2019 | 221.21 Million USD | 6.33% |
| 2018 | 208.04 Million USD | 5.41% |
| 2017 | 197.36 Million USD | -53.1% |
| 2016 | 420.77 Million USD | 249.91% |
| 2015 | 120.25 Million USD | 16.17% |
| 2014 | 103.51 Million USD | 29.85% |
| 2013 | 79.71 Million USD | -6.46% |
| 2012 | 85.22 Million USD | -1.48% |
| 2011 | 86.5 Million USD | -17.52% |
| 2010 | 104.87 Million USD | 27.38% |
| 2009 | 82.32 Million USD | 15.67% |
| 2008 | 71.17 Million USD | 5.92% |
| 2007 | 67.19 Million USD | 46.79% |
| 2006 | 45.77 Million USD | 180.03% |
| 2005 | 16.34 Million USD | -76.43% |
| 2004 | 69.35 Million USD | 1171.48% |
| 2003 | -6.47 Million USD | -8847.3% |
| 2002 | 74 Thousand USD | 0.0% |
| 1999 | -12.9 Million USD | -72.0% |
| 1998 | -7.5 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 30.1 Million USD | 6.36% |
| 2024 Q2 | 28.3 Million USD | -16.76% |
| 2024 Q1 | 34 Million USD | -47.61% |
| 2023 Q2 | 29.3 Million USD | -22.89% |
| 2023 Q1 | 38 Million USD | -48.16% |
| 2023 FY | 164.3 Million USD | -21.76% |
| 2023 Q4 | 64.9 Million USD | 157.54% |
| 2023 Q3 | 25.2 Million USD | -13.99% |
| 2022 Q3 | 78.1 Million USD | 260.48% |
| 2022 Q2 | -48.66 Million USD | -181.46% |
| 2022 Q1 | 59.74 Million USD | -22.82% |
| 2022 Q4 | 73.3 Million USD | -6.15% |
| 2022 FY | 210 Million USD | -23.86% |
| 2021 FY | 275.82 Million USD | 7.82% |
| 2021 Q1 | 65.66 Million USD | 1.18% |
| 2021 Q2 | 65.13 Million USD | -0.8% |
| 2021 Q3 | 67.61 Million USD | 3.8% |
| 2021 Q4 | 77.41 Million USD | 14.49% |
| 2020 Q2 | 62.22 Million USD | -9.84% |
| 2020 Q1 | 69.01 Million USD | 12.11% |
| 2020 Q3 | 59.69 Million USD | -4.05% |
| 2020 Q4 | 64.89 Million USD | 8.71% |
| 2020 FY | 255.82 Million USD | 15.64% |
| 2019 Q3 | 51.63 Million USD | -0.72% |
| 2019 Q1 | 56.02 Million USD | 3.93% |
| 2019 Q2 | 52 Million USD | -7.17% |
| 2019 FY | 221.21 Million USD | 6.33% |
| 2019 Q4 | 61.55 Million USD | 19.22% |
| 2018 Q4 | 53.9 Million USD | 10.82% |
| 2018 FY | 208.04 Million USD | 5.41% |
| 2018 Q3 | 48.64 Million USD | -5.76% |
| 2018 Q1 | 53.88 Million USD | -9.17% |
| 2018 Q2 | 51.61 Million USD | -4.22% |
| 2017 FY | 197.36 Million USD | -53.1% |
| 2017 Q4 | 59.32 Million USD | 23.65% |
| 2017 Q3 | 47.97 Million USD | 2.36% |
| 2017 Q2 | 46.86 Million USD | 8.5% |
| 2017 Q1 | 43.19 Million USD | -86.08% |
| 2016 Q3 | 36.6 Million USD | 0.48% |
| 2016 Q2 | 36.42 Million USD | -2.43% |
| 2016 Q1 | 37.33 Million USD | 1.21% |
| 2016 Q4 | 310.4 Million USD | 747.99% |
| 2016 FY | 420.77 Million USD | 249.91% |
| 2015 Q3 | 28.14 Million USD | 1.07% |
| 2015 FY | 120.25 Million USD | 16.17% |
| 2015 Q4 | 36.89 Million USD | 31.1% |
| 2015 Q2 | 27.84 Million USD | 1.69% |
| 2015 Q1 | 27.37 Million USD | -16.14% |
| 2014 Q2 | 18.4 Million USD | -39.04% |
| 2014 Q3 | 22.26 Million USD | 20.99% |
| 2014 Q4 | 32.64 Million USD | 46.61% |
| 2014 FY | 103.51 Million USD | 29.85% |
| 2014 Q1 | 30.19 Million USD | 138.62% |
| 2013 Q3 | 20.74 Million USD | -10.51% |
| 2013 FY | 79.71 Million USD | -6.46% |
| 2013 Q1 | 23.14 Million USD | 9.33% |
| 2013 Q2 | 23.18 Million USD | 0.17% |
| 2013 Q4 | 12.65 Million USD | -39.0% |
| 2012 Q4 | 21.16 Million USD | 17.9% |
| 2012 Q2 | 21.67 Million USD | -5.38% |
| 2012 Q1 | 22.91 Million USD | 11.59% |
| 2012 Q3 | 17.95 Million USD | -17.19% |
| 2012 FY | 85.22 Million USD | -1.48% |
| 2011 Q2 | 21.6 Million USD | -14.25% |
| 2011 Q3 | 19.17 Million USD | -11.25% |
| 2011 Q4 | 20.53 Million USD | 7.08% |
| 2011 Q1 | 25.19 Million USD | 17.54% |
| 2011 FY | 86.5 Million USD | -17.52% |
| 2010 Q4 | 21.43 Million USD | -0.79% |
| 2010 Q1 | 40.63 Million USD | 90.2% |
| 2010 FY | 104.87 Million USD | 27.38% |
| 2010 Q2 | 20.7 Million USD | -49.06% |
| 2010 Q3 | 21.6 Million USD | 4.37% |
| 2009 Q4 | 21.36 Million USD | 2.55% |
| 2009 Q1 | 20.12 Million USD | 3.25% |
| 2009 Q2 | 20 Million USD | -0.56% |
| 2009 Q3 | 20.83 Million USD | 4.12% |
| 2009 FY | 82.32 Million USD | 15.67% |
| 2008 Q3 | 20.16 Million USD | 17.36% |
| 2008 Q4 | 19.48 Million USD | -3.33% |
| 2008 FY | 71.17 Million USD | 5.92% |
| 2008 Q2 | 17.17 Million USD | 19.72% |
| 2008 Q1 | 14.34 Million USD | -13.67% |
| 2007 Q3 | 16.87 Million USD | -4.33% |
| 2007 Q4 | 16.61 Million USD | -1.51% |
| 2007 Q1 | 15.14 Million USD | -89.4% |
| 2007 FY | 67.19 Million USD | 46.79% |
| 2007 Q2 | 17.63 Million USD | 16.45% |
| 2006 Q1 | 49.3 Million USD | 171.34% |
| 2006 FY | 45.77 Million USD | 180.03% |
| 2006 Q3 | 58.34 Million USD | 0.0% |
| 2006 Q4 | 142.94 Million USD | 145.0% |
| 2006 Q2 | 58.34 Million USD | 18.33% |
| 2005 Q1 | 26.97 Million USD | 0.0% |
| 2005 Q3 | 26.97 Million USD | 0.0% |
| 2005 FY | 16.34 Million USD | -76.43% |
| 2005 Q4 | -69.11 Million USD | -356.23% |
| 2005 Q2 | 26.97 Million USD | 0.0% |
| 2004 FY | 69.35 Million USD | 1171.48% |
| 2003 FY | -6.47 Million USD | -8847.3% |
| 2002 FY | 74 Thousand USD | 0.0% |
| 1999 Q3 | -2.6 Million USD | 0.0% |
| 1999 Q4 | -4.3 Million USD | -65.38% |
| 1999 FY | -12.9 Million USD | -72.0% |
| 1998 FY | -7.5 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -57.66 Million USD | 336.7% |
| AngioDynamics, Inc. | -97.71 Million USD | 239.688% |
| AtriCure, Inc. | -26.68 Million USD | 611.562% |
| Avinger, Inc. | -16.63 Million USD | 920.559% |
| Azenta, Inc. | -73.12 Million USD | 286.664% |
| BioLife Solutions, Inc. | -70.82 Million USD | 292.729% |
| The Cooper Companies, Inc. | 533.1 Million USD | 74.395% |
| Daxor Corporation | -177.07 Thousand USD | 77185.981% |
| Ekso Bionics Holdings, Inc. | -15.11 Million USD | 1003.256% |
| Femasys Inc. | -14.5 Million USD | 1040.833% |
| GlucoTrack, Inc. | -7.1 Million USD | 2021.453% |
| Harvard Bioscience, Inc. | 1.89 Million USD | -7106.969% |
| Hologic, Inc. | 882.6 Million USD | 84.534% |
| ICU Medical, Inc. | 22.82 Million USD | -498.028% |
| Intuitive Surgical, Inc. | 1.76 Billion USD | 92.274% |
| KORU Medical Systems, Inc. | -10.26 Million USD | 1429.117% |
| LeMaitre Vascular, Inc. | 37.08 Million USD | -268.103% |
| Innovative Eyewear, Inc. | -6.9 Million USD | 2078.105% |
| Innovative Eyewear, Inc. | -6.9 Million USD | 2078.105% |
| Microbot Medical Inc. | -9.85 Million USD | 1485.084% |
| Meihua International Medical Technologies Co., Ltd. | 14.67 Million USD | -830.157% |
| Merit Medical Systems, Inc. | 123.94 Million USD | -10.13% |
| Nephros, Inc. | -1.59 Million USD | 8668.738% |
| NovoCure Limited | -232.87 Million USD | 158.616% |
| NEXGEL, Inc. | -3.47 Million USD | 4025.798% |
| NEXGEL, Inc. | -3.47 Million USD | 4025.798% |
| Singular Genomics Systems, Inc. | -102.8 Million USD | 232.781% |
| OraSure Technologies, Inc. | 54.07 Million USD | -152.409% |
| Pro-Dex, Inc. | 7.17 Million USD | -1802.969% |
| Pulse Biosciences, Inc. | -43.57 Million USD | 413.26% |
| Predictive Oncology Inc. | -13.92 Million USD | 1080.51% |
| Precision Optics Corporation, Inc. | -2.72 Million USD | 5110.401% |
| QuidelOrtho Corporation | 139.1 Million USD | 1.869% |
| Repligen Corporation | 54.57 Million USD | -150.11% |
| Sanara MedTech Inc. | -4.21 Million USD | 3338.317% |
| STAAR Surgical Company | 28.09 Million USD | -385.817% |
| Sharps Technology, Inc. | -10.12 Million USD | 1447.928% |
| Utah Medical Products, Inc. | 16.77 Million USD | -713.614% |
| DENTSPLY SIRONA Inc. | -85 Million USD | 260.588% |
| Jin Medical International Ltd. | 2.86 Million USD | -4660.639% |